ESTRO Brachytherapy for Prostate Cancer 2018

• 38/2050 (2%) patients underwent minimal TUR-P.

• 7/38 (18%) with incontinence.

• 2/24 (8%) against 5/14 (36%) with incontinence in case TUR-P was performed <1 or > 2years after implant.

• No correlation of incontinence with D90 prostate or D30 urethra or dose to 5cm 2 urethra.

Teaching Course Dublin 2014